Recce Pharmaceuticals – executive interview

Recce Pharmaceuticals is an innovative, clinical-stage Australian company developing novel, broad-spectrum synthetic polymer anti-infective drugs for the treatment of several infectious diseases including sepsis, complex urinary tract infections, diabetic foot infections and other bacterial skin and skin structure infections.

In this interview, CEO James Graham discusses the company’s latest developments on its lead compound RECCE® 327 (R327) to treat complex drug-resistant infections. He describes the most recent positive human data in the ongoing Phase II study of topical R327 gel (R327G) for the treatment of acute bacterial skin and skin structure infections (ABSSSI). He discusses the upcoming Phase III registrational trial in Indonesia for R327G in the treatment of diabetic foot infections, which could lead to potential commercialisation in ASEAN countries in 2026. James also elaborates on the company’s strategy for furthering development of the intravenous R327 formulation as a treatment for sepsis/urosepsis and complex urinary tract infections, as well as for advancing R327 to US clinical development.